Semaglutide: A Breakthrough in Type 2 Diabetes Management

Dhanshri Mangle; Zoya Fatema Shaikh; Vijay Vaidya; Shilpa Borkar; Jagdish Baheti

doi:10.5281/zenodo.19809216

Review Paper | Open Access
Volume 04 | Issue 04 | Article Id IJPS/260404464

Semaglutide: A Breakthrough in Type 2 Diabetes Management
Dhanshri Mangle* Zoya Fatema Shaikh Vijay Vaidya Shilpa Borkar Jagdish Baheti
Department of pharmaceutics, Kamla Nehru College of Pharmacy, Borkhedi Gate, Butibori, Nagpur, India-441108.

Abstract

Semaglutide has a greater efficacy than other antidiabetic drugs in type 2 diabetes as well as in obesity. It works like a natural hormone to help control blood sugar and aid in weight loss. According to clinical trials, semaglutide beats a lot of traditional diabetes meds at blood-sugar lowering and weight loss. It’s also cardio-protective, something particularly important for diabetes patients who are more likely to develop heart issues. Weekly dosing regimen improves compliance. Semaglutide is effective for a long period of time and hashope for Reno protective effect, hepatoprotective effect. “With its sustained benefits and combined effects on weight loss, blood pressure, lipid levels and other metabolic factors, semaglutide is becoming more commonly recommended by healthcare professionals — earlier in treatment for very high-risk patients.” This breakthrough drug is game-changing for diabetes care, and could have a major impact on patient results.

Keywords

Semaglutide; Diabetes; Obesity; Treatment

Introduction

Type 2 diabetes is a lifelong metabolic disease in which high levels of blood sugar occur due to the body's resistance to insulin or inadequate insulin production. Its incidence has increased inexorably across the world, and is now a global health issue. There are more than 460 million children and adults with diabetes worldwide, and 90% have Type 2 diabetes.

The prevalence of Type 2 diabetes is an important health problem, both in developed and developing countries worldwide. It is linked to many complications, including heart disease, kidney failure, loss of sight and amputation. The economic cost is also substantial, primarily in terms of healthcare expenditures and decreased work performance.

Figure 1. Type 2 diabetes

2. The treatment challenges of Type 2 diabetes exist as follows:

1. Achieving and maintaining glycemic control

2. Managing associated cardiovascular risk factors

3. Preventing long-term complications

4. Addressing medication adherence issues

5. Fighting the disease progression

6. Patient-specific treatment decadence

7. Addressing the costs of long-term care

These are the difficulties that emphasize the most effective, well tolerable patient-friendly alternative in the management of Type 2 diabetes.1-3

Table 1 : classification of antidiabetic drugs.

Category	Class	Examples
Insulin & Analogues	Rapid-acting	Insulin lispro, insulin aspart, insulin glulisine
	Short-acting	Regular insulin
	Intermediate-acting	NPH insulin
	Long-acting	Insulin glargine, insulin detemir, insulin degludec
	Premixed	Mixtures of rapid/short + intermediate insulin
Oral Agents	Insulin Secretagogues
	Sulfonylureas	Glibenclamide, glipizide, gliclazide, glimepiride
	Meglitinides (Glinides)	Repaglinide, nateglinide
	Insulin Sensitizers
	Biguanides	Metformin
	Thiazolidinediones	Pioglitazone, rosiglitazone
	α-Glucosidase Inhibitors	Acarbose, miglitol, voglibose
	DPP-4 Inhibitors (Gliptins)	Sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, teneligliptin
	SGLT-2 Inhibitors (Gliflozins)	Dapagliflozin, canagliflozin, empagliflozin, ertugliflozin
Injectable Non-Insulin Agents	GLP-1 Receptor Agonists	Exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide
	Amylin Analogues	Pramlintide
Emerging / Investigational	Dual GLP-1/GIP Agonists	Tirzepatide
	Oral GLP-1 Agonists	Oral semaglutide

3. Overview of Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes and obesity. The chemical structure, classification, mechanism of action of semaglutide are summarized in this section.2

Chemical Structure and Classification:

Semaglutide, a very long-acting glucagon-like peptide (GLP)-1 receptor agonist, is an incretin mimetic. It has a chemical structure that is derived from human GLP-1(7-37), but with some variations to help increase drug half-life and maintain stability:

Figure 2. Molecular structure Figure 3 . Chemical structure

1. Substitution: Alanine at position 8 is substituted by α-aminoisobutyric acid (Aib) to enhance resistance against degradation by dipeptidyl peptidase-4 (DPP-4).

2. Conjugation with fatty acid: The molecule is conjugated to a C-18 fatty diacid on position 26 through a spacer that enables binding to albumin and increased half-life.

3. Peptide structure: The peptide contains 31 amino acids and has a molecular weight of around 4,114 Da.

Semaglutide has a chemical structure of C165H247N43O53 and structural changes that confer it with a half-life of around 160 hours, facilitating once-weekly dosing.4-7

4.Mechanism of Action of Type 2 diabetes

Table 2 : Mechanism of Action of Type 2 diabetes

Target/System	Mechanism	Effect
Pancreas	↑ Glucose-dependent insulin secretion via cAMP and Ca²? influx	Improves postprandial glucose control
	↓ Glucagon release from α-cells (mainly in hyperglycaemia)	Reduces hepatic glucose output
Gastrointestinal tract	Delays gastric emptying	Prolonged satiety, ↓ food intake
	↓ Intestinal glucose absorption	Improves postprandial glucose profile
Central nervous system	Acts on hypothalamic and brainstem GLP-1 receptors	Appetite suppression, ↓ caloric intake
	Modulates mesolimbic dopamine system	Reduces food craving and reward-driven eating
Cardiovascular system	Promotes natriuresis and vasodilation	Mild reduction in systolic BP
	Favourable impact on lipid metabolism	↓ Total cholesterol and triglycerides
Kidneys	↑ Sodium excretion and urine volume	Supports BP reduction
	↓ Albuminuria and nephron stress	Reno-protective effect in diabetes
Liver	↓ Hepatic glucose production	Enhances overall glycaemic control

Possible effect on type 2 diabetes and obesity. Semaglutide has multiple mechanisms of action, with wide-ranging benefits in type 2 diabetes and obesity.

1. Glycemic control: Increases insulin secretion, decreases glucagon, and lowers hepatic glucose production to decrease fasting and postprandial blood glucose.

2. Lose weight: Decreases appetite, delays stomach emptying, and also influences reward pathways, which can result in significant weight loss.

3. Cardiovascular benefits: Optimize blood pressure, lipid profile, and decrease cardiovascular risk.

4. Renoprotection: Slowing progression of diabetic kidney disease

5. Better liver health: Reduces liver fat, showing promise for people with NAFLD and NASH.

Its peculiar fatty acid linkage results in a long half-life, and it can be dosed weekly to provide stable, sustained effects.

In conclusion, semaglutide exerts continuous benefits for glucose control, body weight, cardiovascular risk, and metabolic health as a long-acting GLP-1 receptor agonist, which can be conveniently taken once weekly for enhanced compliance.8-11

5. The pharmacokinetics and pharmacodynamics of GLP-1 receptor agonists.

Table 3: Pharmacokinetic and pharmacodynamics of GLP-1 receptor agonists.

Parameter	Details
Absorption	• Given by subcutaneous injection • Short-acting forms: rapid uptake, peak levels in ~2–3 h • Long-acting forms: slower uptake, stable plasma concentration • Rate influenced by injection site, local blood flow, and formulation
Distribution	• Small volume of distribution • High plasma protein binding (often >90%) • Limited entry across the blood–brain barrier
Metabolism	• Resistant to enzymatic breakdown by DPP-4 • Minimal hepatic metabolism • Cleared mainly through renal filtration • Pathways differ by molecule (e.g., proteolytic cleavage, protein catabolism)
Excretion	• Mostly excreted via kidneys • Some elimination through bile • Half-life: short-acting ~2–4 h; long-acting ~13 h to 1 week

Figure 4: Semaglutide pharmacokinetics and pharmacodynamics.

6. Time of Onset and Frequency of Dosing:

Table 4: Duration of Action and Dosing Frequency

Category	Drug	Dosing Frequency	Duration of Action
Short-acting GLP-1 RAs	Exenatide	Twice daily (s.c.)	~4–6 h
Short-acting GLP-1 RAs	Lixisenatide	Once daily (s.c.)	~4–6 h
Long-acting GLP-1 RAs	Liraglutide	Once daily (s.c.)	Maintains therapeutic effect over 24 h
	Dulaglutide	Once weekly (s.c.)	Sustained effect through weekly interval
	Semaglutide	Once weekly (s.c.) or once daily (oral)	Weekly (s.c.) or daily (oral) therapeutic coverage
	Exenatide ER	Once weekly (s.c.)	Maintains drug levels for 1 week

7. Challenges and considerations:

• The injectable route of administration (oral semaglutide excepted) also might be a problem for some patients

• It is more expensive compared to most generic oral medicines

• Gastrointestinal adverse reactions, especially during initiation and dose titration

• Few long-term safety data beyond 5-10 years.

In summary, GLP-1 receptor agonists are a major development in the management of type 2 diabetes and provide beneficial effects on glycemia, weight, and cardiovascular risk. Their pharmacokinetic/pharmacodynamic profile enables them to be dosed less frequently via long-acting (LA) preparations which may result in improved patient compliance. The proven effectiveness in lowering HbA1c, weight and cardiovascular risk places GLP-1 RAs as attractive therapeutic options for the management of diabetes, especially for those with obesity or a history of CVD. When comparing them to other medications used for diabetes, from alternative GLP-1 RAs and typical oral agents, they provide a number of benefits in terms of efficacy, safety, and long-term considerations. Nonetheless, cost, manner of application, and likely gastrointestinal side effects provide some guidance for tailoring treatment decisions in people with type 2 diabetes by costs and should be acknowledged when individualizing decisions are made.12-16

8. Safety Profile

Common side effects:

Side effects reported most often with this product are:

• Digestive disturbances: It is very common, especially during the first weeks of treatment, nausea, vomiting, diarrhea, and stomach pain. These side effects tend to get better as your body gets used to treatment.

• Headache: A Mild to moderate headache can be experienced, especially at the beginning of treatment.

• Dizziness: A few patients feel lightheaded or dizzy, which could affect how steady a patient can be and, in turn, affect balance and coordination.

• Fatigue: Some patients experience more fatigue or somnolence.

• Local reactions at the injection site: With injectable forms, you may experience pain, redness, or swelling where the shot was given.

• Hypoglycaemia (low blood sugar): Especially if you take this medicine with other medicines that lower blood sugar.

• Weight changes: primarily weight loss, but weight fluctuation (gain to loss) is common.17-21

Long-term safety data:

Clinical experience over many years in long-term safety studies has contributed invaluable information to the documentation of the profile over an extended period:

• Cardiovascular responses: No increased risk of major cardiac events, including cardiovascular death or sudden cardiac arrest, has been observed in large clinical trials involving treatment following propensity-matched patients with placebo or comparator therapy.

• Pancreatitis risk: Early in its approval, there was concern over a possible association with pancreatitis, but that has not been supported by long-term follow-up studies. But the patients with a previous history of pancreatitis should be observed closely.

• Thyroid safety: Rat studies demonstrated increased rates of thyroid C-cell tumors, yet human data have not shown significant risks. However, patients with a history of a personal or family medullary thyroid carcinoma should refrain from taking the drug.

• Renal: Long-term use does not seem to affect renal function adversely in most patients. There should be monitoring, however, for those with pre-existing renal disease.

• Osteoporosis: A potential effect on bone density has been reported, more frequently in postmenopausal women. Data are long-term and still being acquired to fully elucidate this relationship.

• Gastrointestinal tolerability: Initial gastrointestinal AEs for most patients are ameliorated with continued treatment. Nonetheless, a few of the patients continue to have symptoms with a need for dosage alteration or termination.

• Immunogenicity: the emergence of anti-drug antibodies has been documented in a minority of patients over the long term but does not seem to have a major effect on efficacy or safety for most.22-26

Contraindications and precautions:

The drug is contraindicated in:

• Personal or family history of MTC

• Multiple Endocrine Neoplasia syndromes type 2 (MEN 2)

• Hypersensitivity to the drug or its components

• Pregnancy and breastfeeding (because of insufficient safety data)

The following groups of patients should be cautioned:

• Patients with a history of pancreatitis

• People who have serious gastrointestinal disorders, like gastroparesis

• Individuals with a previous history of diabetic retinopathy

• Patients with renal dysfunction

• Patients who have higher risk of hypoglycemia (especially when used in combination with sulfonylureas or insulin)

• People with previous suicide attempts or suicidal thinking (mentioned as a precaution, despite no proven direct link.27-30

9. Administration and Dosing

Available formulations:31-35

Table 5 : Administration and Dosing

Formulation Type	Dosage Forms	Key Features
Oral	• Tablets (5 mg, 10 mg, 25 mg)	Allows flexible dose titration
	• Extended-release tablets	Once-daily dosing, stable plasma levels
	• Oral solution	Useful for patients with swallowing difficulties or when precise dosing is required
Injectable	• Pre-filled pen devices	Multi-dose cartridge, fixed dose per injection, convenient self-administration
	• Single-use prefilled syringes	Traditional method, suitable for patients or providers preferring single-use dosing
	• Vials	Used mainly in clinical settings, permits customized dosing

10. Patient Selection and Clinical Considerations

Ideal candidates for semaglutide therapy:

Based on the available evidence, an orally administered formulation of semaglutide (a glucagon-like peptide-1 [GLP-1] receptor agonist) has demonstrated substantial clinical benefits in glycaemic control and weight reduction. A general ideal patient profile for patients who might benefit from semaglutide treatment may be as follows:

1. T2DM in adults who have not already achieved recommended glycemic control with diet, exercise and first-line oral ADs.

2. Obese or overweight (BMI ≥ 30 kg/m² or ≥ 27 kg/m² and have at least one weight-related comorbidity) subjects seeking pharmacological treatment for weight management.

3. Especially patients with prior CVD or at high risk of vascular events as semaglutide has proved cardiovascular benefits.

4. Patients who have demonstrated inadequate response to or intolerance of metformin and other oral antidiabetic agents.

5. Patients desiring a once-weekly injection rather than daily oral medications, or more frequent injections.

6. Patients with good compliance with their previous regimens who agree to long-term therapy.

7. Persons who do not have a history of medullary thyroid carcinoma in themselves or close family members; (History of multiple endocrine neoplasia syndrome type 2 (MEN 2) also ruled out.

8. Patients not suffering from a history of pancreatitis or severe gastrointestinal disturbances.

9. Patients are able to accept the potential gastrointestinal side effects of GLP-1 receptor agonists.

10. Patients without previous diabetic retinopathy or who can be closely followed for progression of retinopathy.36-40

11. Semaglutide vs other antidiabetic agents 41-44

Table 6: Semaglutide vs other antidiabetic formulations.

Parameter	Semaglutide (GLP-1 RA)	Metformin (Biguanide)	SGLT2 Inhibitors	DPP-4 Inhibitors	Sulfonylureas	Insulin
Glycemic Control	Strong HbA1c reduction (~1.5–1.8%); lowers fasting plasma glucose significantly	Moderate HbA1c reduction (~1–1.2%); mainly lowers fasting glucose	Moderate (~0.7–1%); lowers both fasting and postprandial glucose	Mild (~0.5–0.8%); modest effect on HbA1c	Strong HbA1c reduction (1.5–2%); rapid onset	Very strong (>2%); most effective in lowering glucose
Weight Loss	Substantial weight loss (5–15%)	Neutral to modest loss	Moderate weight loss (2–4 kg)	Weight neutral	Weight gain (2–3 kg)	Commonly causes weight gain
Cardiovascular Benefits	Proven reduction in MACE; lowers BP and improves lipids	Possible modest CV benefit (UKPDS data)	Strong CV and renal protection; lowers HF hospitalization risk	Neutral; no CV benefit shown	No proven CV benefit; may increase CV risk in some	Mixed: basal insulin neutral; some associated with ↑ CV risk
Durability of Effect	Sustained long-term efficacy; low treatment failure	Good durability, though may decline over years	Maintains effect; moderate durability	Limited durability; glycemic control wanes	Loss of efficacy over time due to β-cell exhaustion	Effective but progressive dose escalation required
Dosing Convenience	Once-weekly (s.c.) or once-daily (oral)	Oral, usually twice daily	Oral, once daily	Oral, once daily	Oral, once or twice daily	Injections (multiple daily or once daily for basal)
Multisystem Effects	Kidney protection, reduced liver fat (NAFLD benefit)	Possible modest renal benefit; improves lipid profile	Strong renal protection, ↓ progression of CKD	Minimal extra-systemic effects	None significant beyond glycemic effect	Indirect renal strain (dose adjustments in CKD)
Safety Profile	Well tolerated; low hypoglycemia risk (unless combined with sulfonylurea/insulin); GI side effects common	Safe, but GI upset and rare lactic acidosis risk	Genitourinary infections, volume depletion; low hypoglycemia	Very safe; few side effects; rare pancreatitis reports	Hypoglycemia common; weight gain; risk of CV events	Hypoglycemia risk high; weight gain; injection burden
Cost-Effectiveness	High cost but prevents long-term complications; multi-organ benefits justify cost	Very cost-effective; first-line therapy	Moderately expensive; justified by CV/renal protection	Moderate cost; modest benefits	Inexpensive; widely used but higher long-term complications	Cost varies; effective but increased long-term complications

FUTURE DIRECTIONS

Semaglutide’s success in type 2 diabetes and obesity encouraged trials in new places:

1. Cardio-vascular disease: Investigation of effects on heart failure, stroke and long-term survival.

2. Kidney disease: The slowing kidney disease progression in low and middle-income countries.

3. Combination therapy: Review of sulfonylureas with SGLT2 inhibitors, DPP-4 inhibitors, and insulin.

4. Paediatric patients: Safety and efficacy have not been established in children with diabetes or obesity.

5. Gestational diabetes: Investigating its possible role in pregnancy with cautious safety monitoring.

6. Liver: Exploring the benefits for NAFLD and NASH.

7. Cognition: Exploring potential neuroprotective roles in diabetes and Alzheimer’s risk.

8. PCOS: Searching for Metabolic and Reproductive Rewards.

9. Prediabetes: Testing the capacity of delay or prevent type 2 diabetes.

10. Formulations: Working on oral and extended release formulations for improved compliance.

CONCLUSION

Semaglutide has rewritten the diabetes-care story by offering potent glycaemic control, substantial weight loss, and cardioprotection in one. Key points:

• Significantly better HbA1c reduction than multiple other agents.

• Provides weight reduction, with an increase in insulin sensitivity.

• Lowers major cardiovascular risks and could safeguard kidney function.

• Once-weekly dosing supports long-term adherence.

•The benefits are lasting, which also helps prevent diabetes-related complications and improves quality of life.

• It may be cost-effective, despite higher initial costs, due to a reduction in future disease burden.

• Its wide range of benefits advocates treatment for diabetes at an earlier stage.

REFERENCES

M?ynarska E, Czarnik W, Dzie?a N, J?draszak W, Majchrowicz G, Prusinowski F, et al. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. IJMS. 2025 Jan 27;26(3):1094.
Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. DDDT. 2025 Apr 1; 19:3509–3537.
Bailey CJ, Flatt PR, Conlon JM. Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides. 2024 Mar 1; 173:171149.
Masuda Y, Ohbayashi K, Iwasaki Y. Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity. Diabetol Int. 2025 May 20;16(3):448–456.
Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. The Journal of endocrinology. 2024 Aug 15;263(1).
Samanta A, Bordbar DD, Weng CY, Chancellor JR. Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy. International ophthalmology clinics. 2024 Dec 23;65(1):23–26.
Kim HS, Jung CH. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? IJMS. 2021 Sept 14;22(18):9936.
Tilinca MC, Burlacu A, Varga A, Tiuca RA. A 2021 Update on the Use of Liraglutide in the Modern Treatment of “Diabesity”: A Narrative Review. Medicina. 2021 June 29;57(7):669.
Gomez-Peralta F, Abreu C. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. DDDT. 2019 Feb 1;13(10053):731–738.
Shi FH, Li H, Cui M, Zhang ZL, Gu ZC, Liu XY. Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2018 June 4;9.
Katsuyama H, Kakazu E, Yanai H, Adachi H, Iida S, Kanto T, et al. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data. Biomedicines. 2024 May 2;12(5):1001.
Hu EH, Tsai ML, Chou TS, Lin Y, Chen TH. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists. Medicina. 2024 Feb 21;60(3):357.
Ibrahim ARN, Orayj KM. Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights. JCM. 2024 Oct 20;13(20):6256.
Stretton B, Kovoor J, Bacchi S, Chang S, Ngoi B, Murray T, et al. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal Medicine Journal. 2023 June 21;53(8):1311–1320.
Klen J, Dolžan V. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. IJMS. 2022 Mar 22;23(7):3451.
Costanzo G, Gullo D, Belfiore A, Curatolo S, Busà B. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinology, Diabetes & Metabolism Case Reports. 2021 July 27;2021.
Mustafa OG, Whyte MB. The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential. Diabetes Metabolism Res. 2019 June 28;35(8).
Rodbard HW. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. Diabetes Technology & Therapeutics. 2018 June 1;20(S2):S2-41.
Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes spectrum?: a publication of the American Diabetes Association. 2017 Feb 23;30(3):202–210.
Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. DDDT. 2025 Apr 1;19:3509–3537.
Nreu B, Dicembrini I, Monami M, Mannucci E, Tinti F. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2023 May 1;48(2).
Quast DR, Kapitza C, Meier JJ, Menge BA, Schenker N, Nauck MA. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes Care. 2020 July 9;43(9):2137–2145.
Nauck MA, Meier JJ. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? European Journal of Endocrinology. 2019 Dec 1;181(6):R211–R234.
Sfairopoulos D, Tigas S, Liatis S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones. 2018 June 12;17(3):333–350.
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018 Oct 1;98(4):2133-2223. doi:10.1152/physrev.00063.2017. PMID: 30067154; PMCID: PMC6170977.
Wilmot EG, Idris I. Early-onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis. 2014 Nov;5(6):234-44. doi: 10.1177/2040622314548679. PMID: 25364491; PMCID: PMC4205573.
Bailey CJ, Flatt PR, Conlon JM. Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides. 2024 Mar 1;173:171149.
Katsuyama H, Kakazu E, Adachi H, Iida S, Mino M, Yanai H, et al. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data. Biomedicines. 2024 May 2;12(5):1001.
Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jan 1;23(3):521–539.
Okamoto A, Hisaoka T, Yokokawa H, Fukuda H, Nagamine T, Naito T. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists. J Diabetes Metab Disord. 2021 Sept 25;20(2):2121–2128.
Honigberg MC, Plutzky J, Mcguire DK, Chang LS, Vaduganathan M, Aroda VR. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. JAMA Cardiol. 2020 June 17;5(10):1182.
Kane MP, Solis-Herrera CD, Triplitt CL. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. American Journal of Health-System Pharmacy. 2020 Dec 23;78(7):556–567.
Cowart K. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother. 2019 Nov 19;54(5):478–485.
Hall S, Clements JN, Isaacs D. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clin Pharmacokinet. 2018 June 19;57(12):1529–1538.
Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes care. 2025 Mar 29;48(5).
Mcguire DK, Cavender MA, Bain SC, Pop-Busui R, Mulvagh SL, Emerson SS, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 Mar 29;392(20):2001–2012.
Koureta E, Cholongitas E. Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration. Front Pharmacol. 2024 Feb 23;15.
Scheen AJ. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs. 2024 Sept 28;84(11):1347–1364.
Stratina E, Stratina E, Cojocariu C, Vlad O, Zenovia S, Trifan A, et al. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics. 2024 July 10;14(14):1475.
Mcguire DK, Mann JFE, Gislum M, Poulter N, Marx N, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obesity Metabolism. 2023 Apr 11;25(7):1932–1941.
Yin YH, Sang LX, Chang B. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World J Gastroenterol. 2023 Dec 28;29(48):6235–6238.
Lempesis IG, Kokkinidis DG, Apple SJ, Kalaitzopoulos DR, Palaiodimos L, Duarte G, et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes Metabolism Res. 2023 July 1;39(6).
Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol. 2021 Dec 7;12(Suppl 1).
Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgraduate Medicine. 2018 Apr 18;130(4):381–393.